GILEAD SCIENCES DL-,001/ US3755581036 /
2024-07-25 8:10:32 AM | Chg. +0.68 | Volume | Bid8:42:39 AM | Ask8:42:39 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
67.90EUR | +1.01% | 0 Turnover: 0.00 |
67.91Bid Size: 240 | 68.01Ask Size: 240 | 84.47 bill.EUR | - | - |
GlobeNewswire
07-01
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...
GlobeNewswire
07-01
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...
GlobeNewswire
06-28
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire
06-26
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
GlobeNewswire
06-26
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
GlobeNewswire
06-18
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...
GlobeNewswire
06-10
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...
GlobeNewswire
05-22
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...
GlobeNewswire
05-14
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
05-09
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...
GlobeNewswire
05-09
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
05-08
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
05-08
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
04-29
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
04-19
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...
GlobeNewswire
04-10
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
04-02
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
GlobeNewswire
04-01
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...